Investment Pitches

Pitch Summary:
AACo is Australia’s oldest beef producer, owning ~1% of the nation’s landmass. Two major shareholders (Tavistock 53%, Tattarang 22%) control 75.5% and continue accumulating, limiting free float and suggesting take-private potential. Shares trade at a 45% discount to NTA, the widest since relisting in 2001. Strategy shifted in 2013 toward branded beef, vertical integration, and premiumization, with long-term reinvestment over dividends. Despite cyclical beef and climate risks, Tavistock and Tattarang are long-term holders and could privatize AACo, offering minorities a fair price based on NTA. Valuation is full on EV/normalized earnings, but NTA supports significant upside. Risks: lack of catalyst, shareholder misalignment, succession uncertainty at Tavistock, operational risks (disease, FX, climate). Upside IRR projected 22–34% if taken private near A$2.55 NTA.

BSD Analysis:
Thesis relies on eventual privatization by controlling shareholders. Downside muted by deep NTA discount, though lack of clear timing/catalyst is a risk. Industry headwinds (climate, cyclical beef) persist but land value underpins floor.

Pitch Summary:
Prudential has transformed from a global conglomerate into a Pan-Asian life and health insurer. It is well positioned for structural tailwinds: rising incomes, under-penetrated insurance markets, and aging demographics across Asia. The pitch emphasizes Prudential’s exposure to China, Hong Kong, and Southeast Asia, where demand for protection and wealth products is expanding. Valuation is undemanding relative to peers, reflecting macro/geopolitical concerns. Risks include regulatory changes in China, FX swings, and execution in balancing growth with solvency. Long-term compounding potential remains attractive given its distribution scale and brand recognition.

BSD Analysis:
A high-quality Asian insurer trading at a discount due to near-term macro fears. Structural growth drivers provide multi-decade tailwinds.

Pitch Summary:
Dave is a cash-advance/payday lender app trading at ~35x P/E-25, pitched as a short with 50%+ downside. Unit economics turn negative after CAC for true MTMs is counted; churn is high, and many customers fall into debt traps. TAM (~25m) near saturation with 12.4m members, and competition from Chime, EarnIn, Brigit, MoneyLion drives CAC up. A new mandatory 5% advance fee post-FTC settlement worsens customer economics, risking churn. Plaid/JPM fee hikes may raise costs further. Credit losses could spike quickly given balance-sheet exposure; any macro downturn hits immediately. Stock up 500% in past year on momentum, but insiders selling. Peer comps valued at 11–15x EBITDA, vs. DAVE ~20x. Base case sees fair value ~$95 (60% downside), with limited bull case upside.

BSD Analysis:
Thin moat, CAC-sensitive, debt-trap optics, regulatory risk. Overvalued vs. peers, with asymmetric downside if credit turns or competition intensifies.

Pitch Summary:
LAND, a farmland REIT, is flagged as a short due to leverage, California concentration, and weakening fundamentals. 67% of portfolio in CA (~2.5x market cap) faces water scarcity, labor shortages (immigration raids), and infestations. Leverage is ~14x debt+preferred to EBITDA; dividend uncovered by FFO. NAV fell 27% 2023–24, management stopped reporting appraisals. Occupancy slipping (96% from 100%), with rising vacancies/non-accruals. Preferred issuance is expensive (10% fees). Peers like FPI are exiting CA exposure and marking down assets by 50%. Valuation is ~20x EBITDA, 3.5–4% equity FCF yield, with risks of dividend cut and impairment. Pros: specialty crop mix, redevelopment optionality, secular farmland scarcity. But author argues downside dominates as cash flows weaken.

BSD Analysis:
Bear case strong: high leverage, weakening tenants, CA exposure risks. Dividend at risk, NAV overstated. If impairments accelerate, equity could break prior valuation floors.

Pitch Summary:
Elme Communities, a D.C.-area multifamily REIT, is pitched as a Buffett-style liquidation with 14–26% IRR potential. The company shed legacy office assets, recast itself around defensive middle-income apartments, and trades at a discount to NAV. Management has realigned capital allocation toward multifamily growth, with NOI supported by constrained supply and resilient demand. Debt is manageable and largely fixed, protecting against interest volatility. Market perception lags reality, as peers trade at higher multiples while Elme remains stuck with an “office” discount. The shareholder base is likely to push for realization of intrinsic value through continued asset rotation or strategic alternatives. Risks include regional rent regulation, policy headwinds, or recessionary pressure on tenants. Overall, the setup suggests a rerating or monetization event that drives strong shareholder returns.

BSD Analysis:
Elme is a clean REIT transition story, with potential catalysts from portfolio optimization and capital market recognition. Investors undervalue its focused exposure to multifamily at a time of housing scarcity.

Pitch Summary:
Tronox, a TiO₂ producer, is pitched as a cyclical turnaround with asymmetric upside. Trades at 0.33x book and 2.5x 2026E P/E. Management is executing $125–175m cost savings, idled a high-cost plant, and is transitioning mining to higher-grade ore. 2025 will be weak due to mine transitions, but 2026 EBITDA guided to $630–740m vs. $410–460m in 2025. Upside levers: pent-up TiO₂ demand, tariffs vs. Chinese supply, monazite/REO byproduct monetization. Insiders are buying stock, and Apollo previously bid $27/sh in 2021. Risks: high leverage ($3bn net debt, 4.8x), cyclical exposure, bankruptcy if cycle fails. Base case: 4x upside if turnaround succeeds, 25% chance of wipeout. Author sees expected value ~3x with prudent position sizing.

BSD Analysis:
Highly levered cyclical—binary profile. Execution on cost saves, tariffs, and demand rebound could quadruple equity, but failure risks insolvency. Position sizing and timing critical.

Pitch Summary:
Global Net Lease is a REIT transitioning from an externally managed, low-quality portfolio into a streamlined, internally managed net lease REIT. Since the internalization and merger with RTL, it has disposed ~$3bn in assets, delevered from 8.3x to ~6.5x, and reduced G&A significantly. Remaining assets are mostly single-tenant retail/industrial, with 66% IG tenancy and manageable lease terms. The stock trades at ~7.4x 2025 AFFO vs. peers at 12–15x+, with an 11% covered dividend and buyback activity. Management guides to $0.93 FY25 AFFO, but normalized run-rate AFFO is closer to $1.00. At even 10x, shares imply 25%+ IRR. Risks: lingering office exposure (~25%), leverage still high vs. peers, historic reputation. Mitigants: active deleveraging, quality tenants, capital return. Author suggests rerating or even takeout potential if undervaluation persists.

BSD Analysis:
Classic “bad to good” REIT story: cleaned-up portfolio, lower G&A, deleveraging. Yield and buybacks provide downside cover. Reputational overhang is real but if valuation gap persists, strategic alternatives are plausible.

Pitch Summary:
McGraw Hill, an education content and platform company, is pitched as a short. Despite a strong brand and footprint in textbooks and digital learning, the business faces secular headwinds from free/open content, OER adoption, and intense competition in edtech. Digital transformation has been slow and costly, while enrollment trends in higher education are stagnant or declining. Leverage is significant, limiting flexibility. The pitch argues that the equity is overvalued relative to growth prospects, and margins will compress as pricing power erodes. Risks to the short include potential private equity interest or faster-than-expected digital transition success.

BSD Analysis:
Classic melting-ice-cube in publishing, where digital transition lags disruptive competition. Short risk is a takeout, but core business trends remain negative.

Pitch Summary:
AirSculpt operates luxury clinics offering minimally invasive fat removal, fat transfer, and skin-tightening procedures. Using proprietary technology, the company differentiates itself from traditional cosmetic surgery. Demand is supported by rising interest in aesthetics and willingness to pay for non-invasive procedures. The author highlights AIRS’s clinic-owned model, which captures full economics but requires upfront investment. With shares at depressed levels, upside stems from continued clinic expansion and margin leverage as newer sites mature. Risks include regulatory scrutiny, consumer discretionary downturns, and competitive encroachment from other med-spa operators. If execution is steady, AIRS could compound growth through unit expansion and pricing power.

BSD Analysis:
A niche but growing aesthetics platform, with leverage to secular trends in wellness and non-invasive beauty. Execution on new clinics is critical for scaling economics.

Pitch Summary:
TopGolf Callaway is preparing to spin off or sell its TopGolf Entertainment business by 2026. The pitch suggests that TopGolf is the higher-growth, higher-valuation segment, while legacy golf equipment and apparel remain slower-growing and cyclical. Separation could unlock value by attracting distinct investor bases: growth/internet for TopGolf, steady cash flow for Callaway. Delays in execution remain a risk, but the author believes strategic rationale is sound. At current multiples, MODG trades at a discount to sum-of-parts valuation, implying upside if separation occurs. Risks include consumer discretionary cyclicality, capex intensity at TopGolf venues, and execution risk in timing the spin.

BSD Analysis:
Sum-of-parts unlock is compelling: TopGolf deserves a higher multiple than bundled MODG. Key is management follow-through on separation; delays remain an overhang.

Pitch Summary:
Enerflex is a Canadian energy infrastructure company, with ~70% of EBITDA from contracted leases and services and 30% from equipment and processing solutions. It has gained share as a leading player in compression, processing, and rental equipment, benefitting from scale and integration. Despite cyclical headwinds in upstream capex, its recurring revenue stabilizes cash flows. Management has focused on deleveraging and asset optimization since the Exterran acquisition. The pitch highlights that valuation underestimates the durability of cash flows and operating leverage into a recovery. Risks include commodity price volatility, customer concentration, and execution on integration. With the stock at ~5x EBITDA, re-rating potential exists if investors recognize the resilience of recurring revenue streams.

BSD Analysis:
The mix of contracted earnings and market-leading competitive position gives Enerflex durability. While oilfield services are cyclical, recurring cash flow warrants a premium multiple relative to peers.

Pitch Summary:
Laureate Education has transformed its portfolio into a focused Latin American higher education company, benefiting from favorable demographics, regulatory support, and expanding middle-class demand. After divesting non-core assets, it now operates a streamlined business with strong cash flow and manageable leverage. The thesis argues that valuation remains compelling, with shares undervalued relative to peers and supported by growth visibility in Brazil, Mexico, and Peru. The company is expected to compound earnings steadily while exploring further operational improvements.

BSD Analysis:
The pitch highlights the attractiveness of higher education in Latin America, where structural demand drivers support long-term growth. While risks include political and regulatory shifts, Laureate’s geographic diversification and cost discipline mitigate downside. Investors should view this as a stable compounder rather than a high-growth story, with steady cash flow and deleveraging creating shareholder value. The thesis rests on rerating potential as the market recognizes Laureate’s focused model and consistent earnings growth.

Pitch Summary:
Intellego made great progress this year. Last year the stock was held back. Customers paid late, cash flow was weak, and they didn't have audited financials. Most of that is now fixed. A big use of Intellego's dosimeters is in UV curing. This is when UV light hardens liquids like glue, coatings, and plastics. Intellego's dosimeters check if these surfaces get the right amount of UV light. The curing market is big. It makes up less than 30% of Intellego's sales today. But it will likely fuel most of Intellego's growth. The big money isn't made at the point of strongest evidence. But at the point of clearest explanation, despite the lack of evidence.

BSD Analysis:
The manager presents Intellego as a turnaround story that has resolved key operational issues from the previous year, including late customer payments, weak cash flow, and lack of audited financials. The company specializes in UV dosimeters used primarily in UV curing applications, where UV light hardens materials like adhesives, coatings, and plastics. The investment thesis centers on the large addressable market for UV curing, which currently represents less than 30% of Intellego's sales but is expected to drive future growth. The manager's final comment suggests this is an early-stage opportunity where the business fundamentals are improving but market recognition has not yet caught up. However, the pitch lacks specific financial metrics, competitive positioning details, or quantitative growth projections. The manager appears to be betting on operational improvements and market expansion in UV curing applications, though the investment case would benefit from more concrete evidence of the turnaround's success and market opportunity sizing.

Pitch Summary:
CareCloud does Revenue Cycle Management (RCM). They make sure U.S. healthcare providers get paid for the care they deliver. The process works like this: 1. Before the visit. Check the patient's insurance 2. During the visit. Turn the doctor's notes into billing codes 3. After the visit. Send those codes as claims to insurers. If insurers reject a claim, CareCloud corrects it and sends it again. Then, it bills the patient for what's left. And collects the payment. RCM runs on software like: - Electronic Health Records (EHR) to store information, and - Practice Management (PM) to handle admin tasks. Together, these make Technology-Enabled Business Solutions (TEBS). TEBS brings in 70% of CareCloud's revenue, and almost all of its cash flow. That's what we'll focus on. Why The Outsourced RCM Market is Growing Outsourced RCM market = RCM market * Outsourcing share 1) RCM market The RCM market grows for 2 reasons: - There's more money to collect, or - It's harder to collect the same money When patients increase and prices go up, there's more money to collect. But insurers and growing billing codes make it harder to collect the same money. - Insurers A few big insurers control most of the U.S. market and set the rules. They often delay or deny claims. And each denial saves them money. Even if they later approve a claim, the delay slows payment, and raises the providers' costs. Unless these incentives change, insurers will continue. - Growing Billing codes Codes are short labels that stand for a test, treatment, or diagnosis. They help systems agree on what care was given. New codes are easy to add. Insurers add codes to control payments and set stricter rules. Drug and device makers add codes so health providers can bill for their products. Public health agencies add codes to track diseases and safety. But old codes are hard to remove. Health providers use old codes for audits and appeals. They need to prove the care they gave, and the payment they requested. Deleting them can cause claim errors, and make reports unreliable. Bills use more than one code at a time. As the list grows, the number of code combinations grows much faster. All this creates more work for doctors and staff. They must write detailed notes. And adjust for each insurer's rules. This admin work isn't fun. U.S. health providers struggle to hire and keep billers. Wages keep rising and many employees leave. Meanwhile, insurers keep raising deductibles and fees. So patients are paying a bigger share of their bills. Collecting from patients takes longer than from insurers. So health providers must provide more payment plans. And follow up more often. Collecting each dollar keeps getting harder and slower. 2) Outsourcing Share RCM outsourcing share grows for 1 reason: - It's better than doing it in-house. Universally, a better result depends on 4 things: 1. How good the result is - (Money collected) 2. How likely it will work - (Claims denied) 3. How long it will take - (Time to cash) 4. How hard it is to get - (Cost) Outsourcing improves all 4 points. And costs less than doing it in-house. Switching to CareCloud improves results even more. The outsourced RCM market has grown 12% a year for the past 10 years. But 23% of healthcare businesses still don't use it. Even though 90% say they want to. Market Opportunity RCM revenue is stable. Clinics almost never switch providers. They'd need to install new systems, retrain staff, and move all billing data. Since RCMs control the flow of money, a switch can interrupt payments. Most providers already run on thin margins, so they avoid the risk. Even if the service isn't great. Today, 1,500-2,000 small RCMs are struggling. They don't win new clients because their tech is outdated. They lack offshore teams, so they outsource and pay more. All this lowers profits and raises costs. Leaving many unprofitable. This opens an opportunity to buy them. But who is it for? Large RCMs avoid buying struggling RCMs. Onboarding takes similar effort for small and large clinics. But small ones bring in much less revenue. So the return isn't worth it. Large RCMs also innovate slowly. Their customers rarely leave, so there's little pressure to improve their service. Today, their real advantage is not technology. But their locked-in customer base. So while their model keeps revenue steady, it limits their ability to buy and fix weak RCMs. That leaves room for mid-sized buyers. A few can buy weak RCMs, cut costs, and upsell services. CareCloud works best because it combines the lowest costs with strong teams and software. The market for buying them is large and growing. There are far more sellers than buyers. And consolidation will take many years. Even if rivals matched CareCloud's cost advantage, CareCloud would still do well. CareCloud's Business Model Most U.S. RCMs grow through sales and marketing. They spend about 1.5% of revenue to get 1% more revenue each year. If the company runs at 20% profit margins, that's a 13% return on investment. It works. But it requires big, expensive U.S. sales teams. Because selling to large hospitals takes a long time. CareCloud grows differently. It buys and fixes struggling RCMs. The business model is strong because they keep: - Low fixed costs. $6M in working cash, and $5M in equipment - Low operational costs. Their Pakistan team costs 85% lower than U.S teams - Fast cash flow. They control the health provider's cash flow. As soon as they receive the revenue, they take a cut This lets them: - Buy struggling RCMs at 1-2x revenue - Cut costs by 40-60% in 3-6 months - Earn 30-40% returns on investment. Even after losing some clients Deals with tiny businesses (<$5M revenue) are even better. The smallest ones are the weakest. So they can't demand much in a sale. This lets CareCloud buy them with little or no cash upfront. CareCloud's Previous Constraints A company doesn't grow to the level of its potential. It grows to the level of its constraints. CareCloud buys RCM companies. It keeps their clients, cuts costs, upsells services, and makes money. To do this well, CareCloud needed 3 things: 1. Cash to buy companies 2. Strong, complete technology 3. A skilled, low-cost team For years, CareCloud had none. They had no money; weak technology; and a small, unskilled team. The service wasn't great. But over time, they improved each part. 1. Cash to buy companies From 2013 to 2021, MTBC (now CareCloud) bought over 20 healthcare IT companies. Taking revenue from $10M to $140M. But they didn't have cash to buy them. So they used preferred shares (loans that can turn into stock). Those preferreds paid a 9% annual dividend. This soaked up most of the company's cash flow. And didn't leave much for growth. The strategy still worked because the business grew faster than the 9% cost. But later, when the preferreds converted into common stock, the dividend payments stopped. That freed up $8M in cash each year. Which now gives CareCloud money to buy RCM companies. 2. Strong, complete technology A complete system needed 3 things: 1. Electronic Health Records (EHR) + Practice Management (PM): Record patient data and run the practice 2. Interoperability: Move data cleanly between systems 3. Automation + analytics: Cut errors and speed up billing To get them, CareCloud bought 3 companies: - CareCloud Corporation (2020): Added cloud EHR/PM and interoperability. - Meridian Medical Management (2020): Added automation (RPA microbots) and analytics. - medSR (2021): Added help in hospital integration and interoperability. Now, the platform is both strong and complete. 3. A skilled, low cost team In 2004, MTBC (now CareCloud) started a small billing team in Pakistan. Over the past 20 years, it grew the team in both size and skill. Today, CareCloud has 3,700 employees. Including 700 in software, and 500 in AI. This allows them to deliver better services, faster than competitors. All while running at 85% lower cost. Every constraint CareCloud solved, made its model stronger. And made it harder for others to compete. Valuation Today On average, similar companies trade at 18x EV / EBITDA: CareCloud trades at 5.7x EV / EBITDA. And its business is better than peers that trade at 3x the price. Valuation In 1-2 Years By the end of 2025, CareCloud will have $20M in cash. That alone could buy $15M in revenue. With debt and seller financing, they could do a $20-25M deal. Adding $6M-10M in EBITDA. This would lift total 2026 EBITDA to $33M-37M. If they repeat the play the year after, EBITDA could reach $39-47M. That translates to $20-27M in free cash flow. Vs today's $100M market cap. The stock is cheap now. And even cheaper looking forward. Why Is CareCloud Cheap? Share count is up. Revenue is down. And TEBS numbers are hidden. This makes it easy to think the management is doing a poor job, and the business is in decline. CareCloud was held back for years by lack of cash, weak technology, and a small team. Now, all 3 constraints are gone. TEBS is a strong business. It uses little money to make a lot. It can keep buying and fixing struggling RCMs for a long time. At 5.7x EBITDA, we're not paying much for the future. If our explanation is better than the market's, we'll make money.

BSD Analysis:
The manager presents a compelling turnaround thesis for CareCloud, arguing that the company has overcome three critical historical constraints: lack of cash, weak technology, and insufficient skilled personnel. The investment case centers on CareCloud's roll-up strategy in the fragmented RCM market, where they acquire struggling competitors at 1-2x revenue multiples and improve margins through cost reduction and operational efficiency. The manager highlights CareCloud's competitive advantages including a 3,700-person offshore team in Pakistan (85% cost savings vs. US), comprehensive technology platform, and strong cash generation model. At 5.7x EV/EBITDA versus peer average of 18x, the valuation appears attractive for a business generating 95-98% collection rates and 30-day payment cycles. The thesis is supported by secular tailwinds including increasing billing complexity, insurer payment delays, and growing outsourcing adoption (currently only 77% penetrated despite 90% wanting to outsource). The manager projects significant EBITDA growth through continued acquisitions, with potential for $20-27M free cash flow against a $100M market cap within 1-2 years.

Pitch Summary:
Viper Energy, Inc. owns and acquires mineral and royalty assets in oil and natural gas properties in the Permian Basin. We like Viper’s royalty-based business model, which provides more consistent and lower-risk exposure to energy markets. The model offers greater visibility into asset development, typically a source of uncertainty in the mineral rights or royalty businesses. The stock underperformed during the period when OPEC+ raised production, sending oil prices and related equities lower. The stock further lagged when oil-price spikes spurred by the Israel-Iran conflict were viewed as temporary and failed to stir recovery in Viper and other commodity-related equities. During the period, we maintained our position.

BSD Analysis:
Viper’s low-cost royalty structure provides high-margin exposure to Permian production without capex risk, but macro-driven oil price weakness weighed on sentiment. The long-term thesis remains intact given steady operator drilling activity and strong reserve life. Shares trade at an attractive FCF yield, with upside tied to commodity stabilization and continued acreage acquisitions.

Pitch Summary:
Axogen, Inc. is a leader in the development of technologies focused on peripheral nerve regeneration and repair. The company’s biologically active nerve graft platform reduces procedural risks by eliminating the need for secondary surgical sites. During the quarter, Axogen reported top-line growth of 17% and reaffirmed its full-year guidance for both revenue growth and gross margin. Despite this positive momentum, shares declined following a weaker-than-expected Q1 gross margin of 72%, which came in below the company’s guided range of 73–75%. The shortfall was attributed to a one-time inventory adjustment and ongoing manufacturing transition. We believe the ramp-up of Axogen’s new manufacturing facility positions the company for long-term margin expansion, with the potential to exceed 80% gross margins. Given our conviction in the operational improvement expected in the second half of the year, we added to our position during the period.

BSD Analysis:
Axogen is positioned for multi-year margin expansion as its new facility scales and manufacturing transitions normalize. Strong double-digit revenue growth reflects rising adoption of nerve regeneration solutions with high clinical differentiation. Shares trade at a discount to long-term growth potential, with catalysts including gross margin recovery, broader surgeon adoption, and potential CMS reimbursement updates.

Pitch Summary:
Ranpak Holdings Corp. is a manufacturer of paper-based protective packaging solutions. Among the many things we like about Ranpak is the sustainability of its products, which are environmentally friendly compared to plastic, foam, and other packaging materials. We also like its consumable business model and attractive unit economics. While underlying demand remained strong, the stock fell in the quarter when profitability was pressured by higher input and logistics costs due to unexpected volume spikes. We believe that these issues will prove to be short-lived resulting in improving margins over the course of the year. We trimmed the position during the period as the company’s execution has been mixed; however, we still believe the secular shift from plastics to paper and the increasing adoption of labor-saving packaging automation technologies will provide long-term tailwinds.

BSD Analysis:
Ranpak remains a structurally advantaged ESG-focused packaging supplier with recurring consumable revenue and long-term demand visibility. While margin volatility reflects temporary cost pressures, automation initiatives and operating leverage should restore profitability. Shares trade below intrinsic value versus sustainable packaging peers, offering re-rating potential as execution stabilizes. Key catalysts include easing logistics costs, automation adoption, and pricing improvements.

Pitch Summary:
The Cooper Companies, Inc. is a medical technology firm with two main divisions: CooperVision, a leader in contact lenses, and CooperSurgical, which focuses on women’s health, including reproductive care and fertility. Despite strong quarterly performance and a full-year guidance raise, the stock fell on slightly lowered growth forecasts for the contact lens industry. While still growing faster than the industry, the lower guidance brought a punitive response from investors, a recurring theme for healthcare companies. We maintain confidence in the company’s fundamentals and long-term growth potential, and slightly trimmed our position.

BSD Analysis:
Cooper remains a high-quality compounder with leadership in the global contact lens market and exposure to secular fertility trends. Near-term sentiment weakness reflects modestly reduced market growth expectations rather than deterioration in fundamentals. Shares trade at a discount to historical P/E multiples, offering upside as industry growth normalizes. Catalysts include product launches, margin expansion within CooperSurgical, and stabilization of contact lens demand.

Pitch Summary:
Halozyme Therapeutics, Inc. is a leading drug delivery platform company built around its proprietary and commercially validated ENHANZE® technology. This innovative enzyme enables the subcutaneous delivery of biologics and fluids, transforming hours-long intravenous (IV) infusions into quick injections that can be delivered in just minutes. Shares of Halozyme declined during the period following news that the Centers for Medicare & Medicaid Services (CMS) may reconsider how it classifies reformulated drugs using ENHANZE. Under the proposed change, such formulations may no longer qualify as “new drugs,” potentially subjecting them to Medicare price negotiations earlier than previously expected. While the proposal remains under review, we believe ENHANZE continues to offer meaningful advantages… We slightly reduced our position in the company during the quarter.

BSD Analysis:
Despite platform strength and widespread pharma partnerships, Halozyme faces reimbursement overhang risk that could compress long-term royalty economics. The company’s high-margin royalty model supports strong cash generation, but CMS rule changes may lower future uptake or pricing. Shares trade below intrinsic NPV of partnerships, with upside tied to regulatory clarity and pipeline expansion.

Pitch Summary:
Ziff Davis, Inc. operates businesses in two primary segments: business cloud services and digital media. The company delivered solid results for the quarter, beating revenue and EBITDA expectations while management confirmed annual guidance and called for accelerating quarterly growth. However, shares came under pressure as investors did not see enough evidence of improved organic growth or significant acquisitions. We were encouraged by early signs that the company’s acquisition strategy is beginning to bear fruit and believe it is nearing an inflection point for improved organic growth, which we view as a potential catalyst for investor sentiment. In addition, Ziff Davis recently filed a copyright infringement lawsuit against OpenAI, which could result in a favorable settlement over the intermediate term. We modestly trimmed our position in the company during the period.

BSD Analysis:
Ziff Davis continues to face skepticism around its organic growth trajectory despite improving execution and stable M&A optionality. Shares trade below historical EV/EBITDA averages, reflecting uncertainty in digital advertising and cloud services growth durability. A successful legal outcome or renewed acquisition cadence could reaccelerate sentiment, while improving EBITDA margins offer downside support. Key risks include muted digital ad markets and slower cloud adoption trends.